The price drop on bpax seems typical of today's stock market; One piece of bad news outweighs all the factual data the company has. At the very least this should be at $1.20, but one bad drug review dropped where it is now
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.